Anavex withdraws EU marketing application for Alzheimer's drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Anavex Life Sciences Provides Comprehensive Regulatory Update
March 30, 2026 7:30 AM EDTDialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimers disease
Additional data submitted to the U.S. FDA with the objective to discuss potential pathways towards a New Drug Application (NDA) for the treatment of early Alzheimers disease
Additionally, Anavex has engaged in discussions with EU regulators regarding blarcamesine for Parkinsons disease and rare diseases, including Rett syndrome
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a... More
